Evidence map›Paper›PMID 32293756›Full record

ArticleStatistics in medicine2020

A flexible nonlinear mixed effects model for HIV viral load rebound after treatment interruption.

Rui Wang, Ante Bing, Cathy Wang, Yuchen Hu, Ronald J Bosch, Victor DeGruttola

Abstract read
In one paragraph

Article in Statistics in medicine, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Stochastic Version of EM Algorithm for Nonlinear Random Change-Point Models.Proceedings of the International Conference on Statistics, Theory and Applications (ICSTA ...) · 2021
    Article
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors.

Rui WangDepartment of Population Medicine, Harvard Pilgrim Health Care Institute and Harvard Medical School, Boston, Massachusetts, USA.ORCID 0000-0001-5007-193X
Ante BingDepartment of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Cathy WangDepartment of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.ORCID 0000-0001-7466-0034
Yuchen HuDepartment of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Ronald J BoschDepartment of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.
Victor DeGruttolaDepartment of Biostatistics, Harvard T. H. Chan School of Public Health, Boston, Massachusetts, USA.

Funding

Leadership and Operations Center (LOC), AIDS Clinical Trials Group (ACTG); LOC 1/UM1AI068636 · NIAID · UNIV OF NORTH CAROLINA CHAPEL HILL · PI Joseph J Eron, RAJESH T GANDHI · 2011 to 2026
$1073.1M
Statistical and Data Management Center (SDMC), AIDS Clinical Trials Group (ACTG)UM1AI068634 · NIAID · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI Marlene Ann Cooper, Michael David Hughes · 2011 to 2026
$246.6M
UC San Diego Clinical and Translational Research InstituteUL1TR001442 · NCATS · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI FIRESTEIN, GARY S, HOGARTH, MICHAEL · 2015 to 2024
$88.3M
Revealing Reservoirs during Rebound (R3)P01AI131385 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI DEGRUTTOLA, VICTOR GERARD · 2017 to 2021
$8.7M
Methods to Advance the HIV Prevention Research AgendaR37AI051164 · NIAID · HARVARD SCHOOL OF PUBLIC HEALTH · PI DEGRUTTOLA, VICTOR GERARD · 2012 to 2019
$3.3M
Network modeling and robust estimation of the intraclass correlation coefficient to inform the design and analysis of cluster randomized trials for infectious diseasesR01AI136947 · NIAID · HARVARD PILGRIM HEALTH CARE, INC. · PI WANG, RUI · 2018 to 2020
$759k
NCATS NIH HHS UL1 TR001442NIAID NIH HHS P01 AI131385NIAID NIH HHS R01 AI136947NIAID NIH HHS R37 AI051164NIAID NIH HHS UM1 AI068634NIAID NIH HHS UM1 AI068636
6 · The paper itself

Abstract

Characterization of HIV viral rebound after the discontinuation of antiretroviral therapy is central to HIV cure research. We propose a parametric nonlinear mixed effects model for the viral rebound trajectory, which often has a rapid rise to a peak value followed by a decrease to a viral load set point. We choose a flexible functional form that captures the shapes of viral rebound trajectories and can also provide biological insights regarding the rebound process. Each parameter can incorporate a random effect to allow for variation in parameters across individuals. Key features of viral rebound trajectories such as viral set points are represented by the parameters in the model, which facilitates assessment of intervention effects and identification of important pretreatment interruption predictors for these features. We employ a stochastic expectation-maximization (StEM) algorithm to incorporate HIV-1 RNA values that are below the lower limit of assay quantification. We evaluate the performance of our model in simulation studies and apply the proposed model to longitudinal HIV-1 viral load data from five AIDS Clinical Trials Group treatment interruption studies.

Indexed as

Anti-HIV AgentsHIV InfectionsAlgorithmsHumansNonlinear DynamicsRNA, ViralViral LoadAnti-HIV AgentsRNA, Viralcensoringimputationiterativenonlinearviral rebound

Identifiers

PMID32293756
PMCPMC8081565

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.